{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:54:37Z","timestamp":1766400877671,"version":"3.48.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2601460","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T16:59:46Z","timestamp":1766336386000},"page":"2264-2271","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Body weight distribution of US patients with myasthenia gravis"],"prefix":"10.1080","volume":"28","author":[{"given":"Kevin","family":"Tse","sequence":"first","affiliation":[{"name":"argenx US Inc.","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Sato","sequence":"additional","affiliation":[{"name":"ZS Associates","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit R.","family":"Menon","sequence":"additional","affiliation":[{"name":"ZS Associates","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Du","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc.","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia Z.","family":"Qi","sequence":"additional","affiliation":[{"name":"argenx US Inc.","place":["Boston, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1339167"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3233\/jnd-170294"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S296714"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282x-anp-2022-s105"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2024.02.392"},{"volume-title":"Vyvgart","year":"2025","key":"e_1_3_4_7_1","unstructured":"Vyvgart [package insert]. Boston (MA): argenx; 2025."},{"volume-title":"Vyvgart Hytrulo","year":"2025","key":"e_1_3_4_8_1","unstructured":"Vyvgart Hytrulo [package insert]. Boston (MA): argenx; 2025."},{"volume-title":"Ultomiris","year":"2024","key":"e_1_3_4_9_1","unstructured":"Ultomiris [package insert]. Boston (MA): Alexion Pharmaceuticals, Inc.; 2024."},{"volume-title":"Rystiggo","year":"2025","key":"e_1_3_4_10_1","unstructured":"Rystiggo [package insert]. Atlanta (GA): UCB Pharma; 2025."},{"volume-title":"Zilbrysq","year":"2025","key":"e_1_3_4_11_1","unstructured":"Zilbrysq [package insert]. Atlanta (GA): UCB Pharma; 2025."},{"volume-title":"Soliris","year":"2025","key":"e_1_3_4_12_1","unstructured":"Soliris [package insert]. Boston (MA): Alexion Pharmaceuticals, Inc.; 2025."},{"volume-title":"Imaavy","year":"2025","key":"e_1_3_4_13_1","unstructured":"Imaavy [package insert]. Raritan (NJ): Janssen; 2025."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00383-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1448803"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00378"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00077-7"},{"key":"e_1_3_4_19_1","unstructured":"Rystiggo (rozanolixizumab) Integrated Review: Food and Drug Administration. 2023 [cited 2025 July]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/761286Orig1s000IntegratedR.pdf"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00080-7"},{"key":"e_1_3_4_21_1","unstructured":"Ultomiris (ravulizumab) Assessment Report: European Medicines Agency. 2022 [cited 2025 July]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/ultomiris-h-c-004954-ii-0026-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11699-x"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(17)30369-1"},{"issue":"36","key":"e_1_3_4_24_1","first-page":"1","article-title":"Anthropometric reference data for children and adults: United States, 2015\u20132018","volume":"3","author":"Fryar CD","year":"2021","unstructured":"Fryar CD, Carroll MD, Gu Q, et al. Anthropometric reference data for children and adults: United States, 2015\u20132018. Vital Health Stat 3. 2021;3(36):1\u201344.","journal-title":"Vital Health Stat 3"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000201501"},{"key":"e_1_3_4_26_1","unstructured":"Ultomiris dosing overview [Website]. Boston (MA): Alexion Pharmaceuticals Inc.; 2025 [updated 2025; cited 2025 September 16]. Available from: https:\/\/ultomirishcp.com\/gmg\/dosing"},{"key":"e_1_3_4_27_1","unstructured":"Park M Ting A Nair A et\u00a0al. Characteristics of patients with generalized myasthenia gravis initiating rozanolixizumab treatment in the United States. Poster presented at the Myasthenia Gravis Foundation of America Scientific Session at the Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine. San Francisco CA USA; 2025."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-439"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11111139"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001126"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.518"},{"issue":"3","key":"e_1_3_4_34_1","first-page":"S65","article-title":"Economic evaluations of FcRn inhibitors in generalized myasthenia gravis","volume":"31","author":"Jefferson M","year":"2025","unstructured":"Jefferson M, Qi C, Yang H, et al. Economic evaluations of FcRn inhibitors in generalized myasthenia gravis. J Manag Care Spec Pharm. 2025;31(3-a):S65.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2601460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:46:04Z","timestamp":1766400364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2601460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2601460"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2601460","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"type":"print","value":"1369-6998"},{"type":"electronic","value":"1941-837X"}],"subject":[],"published":{"date-parts":[[2025,12,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}